ArticleMolecular genetics & genomic medicine2026
Newborn Screening of Primary Carnitine Deficiency and Prenatal Genetic Diagnosis for a Recurrence-Risk Family.
Article in Molecular genetics & genomic medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundPrimary carnitine deficiency (PCD) is a treatable autosomal recessive disorder caused by SLC22A5 gene variants and included in newborn screening widely. However, its prevalence and variant spectrum vary greatly, and prenatal diagnosis for recurrence-risk families remains rare. This study assessed tandem mass spectrometry (MS/MS) combined with genetic testing in NBS and prenatal diagnosis of PCD in Yancheng, China, and described the local prevalence and variant characteristics.
methodsFrom 2015 to 2024, free carnitine (C0) levels were measured in neonatal dried blood spot (DBS) samples by MS/MS for PCD screening. Newborns with persistently low C0 levels were recalled for diagnostic evaluation. At diagnosis, the C0 levels in both neonatal and maternal blood were measured, and next-generation sequencing was performed for SLC22A5 variants in the newborns. For the recurrence-risk family with a previous proband, Sanger sequencing was used to confirm the parental origin of the proband's variants, and prenatal diagnosis with amniotic fluid was performed in the subsequent pregnancy.
resultsCombined MS/MS and genetic testing led to the diagnosis of 17 newborns with PCD (15 molecularly confirmed with biochemical results, two clinically inferred) and three newborns with maternal carnitine deficiency among the 152 newborns with persistently low C0 levels on re-screening. In these 17 PCD newborns, 10 distinct variant sites were detected, of which missense variants predominated, with c.1400C>G (p.S467C) being the most frequent (13/32, 40.63%). For the proband in this recurrence-risk family, the two pathogenic variants were inherited from each parent. The fetus carried only the maternal variant, without postnatal anomalies.
conclusionNBS using MS/MS combined with genetic testing facilitates early diagnosis and classification of PCD. The screening-detected prevalence of PCD in Yancheng was 1:25,852, with c.1400C>G (p.S467C) as the hotspot variant. Genetic testing of SLC22A5 provided effective prenatal diagnosis for the recurrence-risk family.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.